GoAI
Get started
SciSparc Ltd. logo

SciSparc Ltd.

SPRC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.695

−$0.045 · -0.67%

Aug 21, 4:00 PM ET

SPRC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

17

Strong Down

Sentiment

54

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Oz Adler
Listed since
Aug 30, 2021
Employees
3

Market position

Day range

Current $6.695

52-week range

Current $6.695

Open
$6.695
Previous close
$6.74
Volume
2.48K
0× average
Average volume
869.91K
Average daily volume
Market cap
387.23K USD
Beta
2.45
Market reference 1
50-day average
$6.2687
+6.80% above average
200-day average
$8.8632
-24.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
164.67M USD
P/E (TTM)
-0.03×
P/B (TTM)
0.06×
P/S (TTM)
0.45×
EV / EBITDA
-13.37×
Earnings yield
-7.21%
Free cash flow yield
-2.45%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
46.38%
Operating margin
-1022.08%
Net margin
-1422.78%
Return on equity
-287.31%
Return on assets
-159.79%
Return on invested capital
-152.55%

Financial health

Debt / equity
0.09×
Current ratio
2.41×
Altman Z-score
-22.15
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends249%-359%-967%-1575%Gross margin, FY2021: 96.91%Gross margin, FY2022: 76.10%Gross margin, FY2023: 76.28%Gross margin, FY2024: 38.74%Gross margin, FY2025: 73.71%Operating margin, FY2021: -539.57%Operating margin, FY2022: -547.88%Operating margin, FY2023: -200.52%Operating margin, FY2024: -560.18%Operating margin, FY2025: -1022.08%Net margin, FY2021: -542.66%Net margin, FY2022: -192.43%Net margin, FY2023: -177.91%Net margin, FY2024: -481.16%Net margin, FY2025: -1422.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.91%. Gross margin FY2022 76.10%. Gross margin FY2023 76.28%. Gross margin FY2024 38.74%. Gross margin FY2025 73.71%. Operating margin FY2021 -539.57%. Operating margin FY2022 -547.88%. Operating margin FY2023 -200.52%. Operating margin FY2024 -560.18%. Operating margin FY2025 -1022.08%. Net margin FY2021 -542.66%. Net margin FY2022 -192.43%. Net margin FY2023 -177.91%. Net margin FY2024 -481.16%. Net margin FY2025 -1422.78%.

Income trends

Revenue

856K USD-34.46%

Operating income

−8.75M USD-19.59%

Net income

−12.18M USD-93.81%
Income trends across reported periods4.38M USD−1.64M USD−7.66M USD−13.68M USDRevenue, FY2021: 1.07M USDRevenue, FY2022: 1.35M USDRevenue, FY2023: 2.88M USDRevenue, FY2024: 1.31M USDRevenue, FY2025: 856K USDOperating income, FY2021: −5.77M USDOperating income, FY2022: −7.38M USDOperating income, FY2023: −5.77M USDOperating income, FY2024: −7.32M USDOperating income, FY2025: −8.75M USDNet income, FY2021: −5.8M USDNet income, FY2022: −2.59M USDNet income, FY2023: −5.12M USDNet income, FY2024: −6.28M USDNet income, FY2025: −12.18M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.07M USD. Revenue FY2022 1.35M USD. Revenue FY2023 2.88M USD. Revenue FY2024 1.31M USD. Revenue FY2025 856K USD. Operating income FY2021 −5.77M USD. Operating income FY2022 −7.38M USD. Operating income FY2023 −5.77M USD. Operating income FY2024 −7.32M USD. Operating income FY2025 −8.75M USD. Net income FY2021 −5.8M USD. Net income FY2022 −2.59M USD. Net income FY2023 −5.12M USD. Net income FY2024 −6.28M USD. Net income FY2025 −12.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue856K USD1.31M USD2.88M USD1.35M USD1.07M USD
Cost of goods sold225K USD800K USD683K USD322K USD33K USD
Gross profit631K USD506K USD2.2M USD1.03M USD1.04M USD
Research and development2.19M USD1.82M USD1.64M USD2.8M USD1.99M USD
Selling, general, and administrative5.44M USD5.81M USD6.13M USD6.27M USD3.64M USD
Operating expenses9.38M USD7.82M USD7.97M USD8.41M USD5.77M USD
Interest income207K USD421K USD—1.24M USD18K USD
Interest expense11K USD30K USD9K USD36K USD12K USD
Depreciation and amortization234K USD482K USD538K USD187K USD33K USD
Operating income−8.75M USD−7.32M USD−5.77M USD−7.38M USD−5.77M USD
Net income−12.18M USD−6.28M USD−5.12M USD−2.59M USD−5.8M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.7

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates39.79-32.2-104.19-176.18Q3 '22Q2 '23Q3 '23Q2 '24Q3 '24Q2 '25Q3 '25Q2 '26
Q3 2022, reported Jul 28, 2022: actual -42.12, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 27, 2023: actual 24.9, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 7, 2023: actual -19.53, estimate —, surprise —, Comparison unavailable. Q2 2024, reported May 6, 2024: actual -7.33, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Jul 1, 2024: actual -15.3, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 24, 2025: actual -12.63, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 24, 2025: actual -161.28, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 23, 2026: actual -0.702, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates2.1M1.51M923.22K335.75KQ2 '22Q2 '23Q3 '23Q2 '24Q3 '24Q2 '25Q3 '25Q2 '26
Q2 2022, reported Apr 4, 2022: actual 1.07M USD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 27, 2023: actual 1.35M USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 7, 2023: actual 1.97M USD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported May 6, 2024: actual 907K USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Jul 1, 2024: actual 840K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 24, 2025: actual 466K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 24, 2025: actual 461K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 23, 2026: actual 395K USD, estimate —, surprise —, Comparison unavailable.

SPRC news

globenewswire.com

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing

Read source
thenewswire.com

Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement

T oronto, Ontario – TheNewswire - August 17, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC),…

Read source
thenewswire.com

NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement

Toronto, Ontario – August 12, 2026 – TheNewswire - NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC),…

Read source
globenewswire.com

SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company…

Read source
thenewswire.com

NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq:…

Read source
globenewswire.com

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 4, 2026

1:9

Stock split

Effective Jul 3, 2025

1:21

Stock split

Effective Sep 28, 2023

1:26

SPRC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SPRC

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
817.51K
Weight
—
AUM
27.89B USD
Expense ratio
0.33%
Price / 1D
$94.24+0.75%
Avantis Emerging Markets Value ETF logoAvantis Emerging Markets Value ETFAVES
Market value
140.94K
Weight
0.01%
AUM
1.5B USD
Expense ratio
0.36%
Price / 1D
$65.16+0.51%
Avantis Emerging Markets Small Cap Equity ETF logoAvantis Emerging Markets Small Cap Equity ETFAVEE
Market value
95.52K
Weight
0.08%
AUM
122.3M USD
Expense ratio
0.42%
Price / 1D
$68.1949+0.35%
Avantis Emerging Markets ex-China Equity ETF logoAvantis Emerging Markets ex-China Equity ETFAVXC
Market value
89.15K
Weight
0.02%
AUM
445.33M USD
Expense ratio
0.33%
Price / 1D
$81.593+0.73%

Continue in GoAI

Research SPRC

research.disclaimer